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Head and neck squamous cell carcinoma (HNSCC) is the sixth cancer on incidence worldwide. Tobacco 
and alcohol consumption are the most classical risk factors associated with its development. Autophagy 
process has a dual effect both in tumourigenesis and tumour suppressing activity. To investigate the 
importance of this pathway in HNSCC susceptibility, a risk factor matched case-control association 
study was performed with four candidate polymorphisms in autophagy genes (ATG2B, ATG5, ATG10, 
ATG16L1). We found an association between the variant in ATG10 rs1864183 and a higher susceptibility 
to develop laryngeal cancer, ATG2B rs3759601 and pharyngeal cancer and ATG16L1 rs2241880 and oral 
carcinoma. ATG5 rs2245214 SNP was not associated with any location. Overall, our results indicate the 
importance of the autophagy pathway in the susceptibility of head and neck squamous cell carcinoma 
and demonstrate the heterogeneity between its locations encompassed under a single terminology.
Head and neck cancer (HNC) groups a set of different tumours located in the upper aero-digestive via. It 
includes tumours located in the lips, oral cavity, pharynx (nasopharynx, oropharynx and hypopharynx) as well 
as larynx, salivary glands and thyroid glands among others1. It is the sixth cancer type on incidence worldwide. 
Approximately 600.000 new cases are diagnosed each year and only 40–50% reach the five-years survival rate2 
causing an annual death of 271.000 patients3, 4. Not all HNC present similar histology, prevailing in 90% of cases 
the squamous cell carcinomas which initiate in the mucosa1.
Classic factors associated to the development of head and neck squamous cell carcinoma (HNSCC) are tobacco 
and alcohol consumption. At least 75% HNSCC are attributable to the combination of both carcinogens5, 6. 
Moreover, different epidemiological studies have revealed the existence of other related factors, both environmen-
tal and genetic. In the last years the viral aetiology has been implicated in the development of HNSCC. This is the 
case of Epstein-Barr virus (EBV) in nasopharynx and the human papillomavirus (HPV), mainly subtype 16, in 
oral cavity and oropharynx tumours7. However, the carcinogenesis procedure triggered by viral infection identi-
fies a totally different entity than the one produced by tobacco and alcohol8, 9. On the other hand, the observation 
of familial aggregations in HNSCC suggests the existence of genetic predisposition factors. Lots of case-control 
studies have determined this genetic susceptibility, increasing the risk between 2–4 times for first grade HNSCC 
patients family10.
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Aero digestive tract carcinogenesis involves altered carcinogen metabolism, a modified DNA repair, cell cycle 
disruption and deregulation of pathways implicated in immunity, inflammation and cellular components degra-
dation11. Allelic variants of genes implicated in essential cellular pathways play a very important role in tumour 
development as well as in treatment response. Polymorphism is defined as that mutation or variant which is found 
in at least 1% of the general population. Single Nucleotide Polymorphism (SNP) is the most abundant form of 
genetic variation11.
Macro-autophagy is the catabolic process of damaged organelles or protein recycling under nutrient starva-
tion or stress. It starts with the double-membrane autophagosome formation and finishes with a fusion with the 
lysosomes to form the autophagolysosome which contains hydrolases for the degradation of the contents. This 
autophagosome complex is synthesised by autophagy-related genes (ATG)12. Autophagy takes part into both 
the initiation and prevention of cancer, and its function can be altered during tumour progression13. Although 
autophagy has a suppressing tumour activity, it is also involved in tumourigenesis by inhibiting cellular death and 
increasing drug resistance. It participates in important pathways connected to carcinogenesis as well as immune 
response, inflammation and genome stability14. However the precise mechanisms that involve autophagy in can-
cer are not yet defined15. In HNSCC, autophagy mechanisms are still unknown and they can symbolize an impor-
tant area for future research16.
To achieve our aim a candidate gene analysis was performed to study SNPs in autophagy genes: ATG2B, 
ATG5, ATG10, ATG16L1 (Table 1) that could be associated to the risk to suffer HNSCC in a Spanish population. 
This association study was performed with a control group, selecting a cohort of subjects matched in gender, age 
and the two most important environmental factors involved in the development of HNSCC, tobacco and alcohol 
consumption, avoiding confounding variables and considering genetic background on its own.
Results
A total of 450 patients distributed in 213 cases of larynx carcinoma, 165 of pharynx carcinoma and 72 of oral 
cavity were included in the study. The descriptive study of the global analysis by location showed some statistical 
differences between sex, age, tobacco and alcohol intake (Table 2). For this reason, SNPs analysis was calculated 
with an adjustment for these variables in the different locations.
The global study of susceptibility in laryngeal cancer (Table 3) showed an association between the heterozy-
gote genotype of ATG2B rs3759601 and a lower risk to develop laryngeal squamous cell carcinoma, p = 0.049 





change Chr. location Assay ID HWE*
ATG2B rs3759601 C > G Q1383E 14:96311131 c_9690166_10 >0.05
ATG5 rs2245214 C > G Intronic 6:106214866 c_3001905_20 >0.05
ATG10 rs1864183 C > T T212M 5:82253397 c_11953871_20 >0.05
ATG16L1 rs2241880 T > C T300A 2:233274722 c_9095577_20 >0.05
















P-valueN % N % N % N % N %
Age (years) 61.97 ± 9.242 52.18 ± 12.752 0.000 62.96 ± 8.987 0.000 61.00 ± 9.086 0.000 61.29 ± 10.232 0.000
Sex








Male 398 88.4 123 48.6 200 93.9 142 86.1 56 77.8
Tobacco smoking








 < 20 PPY 62 13.8 72 28.5 20 9.4 30 18.2 12 16.7
 > 20 PPY 352 78.2 146 57.7 180 84.5 121 73.3 51 70.8
Missing 14 3.1 12 4.7 6 2.8 6 3.6 2 2.8
Packs per year 57.00 ± 36.512 31.88 ± 28.861 0.000 61.17 ± 35.498 0.000 54.91 ± 36.947 0.000 49.55 ± 37.366 0.000
Alcohol drinking








 < 14 SDU/week 94 20.9 46 18.2 44 20.7 31 18.8 19 26.4
 > 14 SDU/week 238 52.9 48 19.0 114 53.5 96 58.2 28 38.9
Missing 13 2.9 6 2.4 2 0.9 11 6.7 0 0
SDU/week 30.07 ± 39.349 9.02 ± 21.213 0.000 27.81 ± 37.008 0.000 36.27 ± 40.710 0.000 23.43 ± 41.553 0.000
Table 2. Descriptive case-control study. P-values related to controls. Statistically significant results in bold.
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found. The heterozygous genotype had a close relationship with an increased risk to develop laryngeal cancer 
(p = 0.059, OR = 1.648) (Table 3).
Analysis in pharyngeal squamous cell carcinoma showed that carriers of GG genotype in the SNP ATG2B 
rs3759601 had an increased risk to develop this tumour, both in the codominant and the recessive model, 
p = 0.013 OR = 2.493 (1.212–5.129) (Table 3). No other associations were found in the rest of SNPs between cases 
and controls.
ATG16L1 rs2241880 was unequally distributed in oral cavity cancer (Table 3). Patients with the less common 
allele C had higher risk to suffer from oral cavity cancer in our sample, p = 0.017 in recessive model, OR = 2.214 
(1.150–4.263).
Due to the great significant differences in all the variables between groups, a second analysis was proposed 
by the Propensity Score method (PS). After its application we have totally paired 126 larynx, 100 pharynx and 70 
oral cavity tumours according to sex, packs of tobacco per year (PPY) and standard drink units per week (SDU/
week) with their specific control groups (Table 4). This method allowed us to corroborate the previous analysis 
avoiding the possible confounding variables. Quantitative age was also included as an adjustment variable in the 
logistic regression analysis of the laryngeal susceptibility study due to the significant differences between groups 
in the ANOVA test (p-value < 0.05) (Table 4). Because of pharyngeal and oral cavity carcinomas were paired by 
age, adjustment by quantitative age was not necessary (Table 4).
Once again, ATG2B rs3759601 heterozygote genotype was associated with a lower risk to develop laryngeal 
cancer p = 0.028 OR = 0.535 (0.307–0.935) (Table 5). Although not statistically significant in the previous anal-
ysis (p = 0.059), we found a similar result in ATG10 rs1864183 and a higher risk to develop laryngeal cancer in 
patients carrying the T allele, p = 0.026 OR = 1.888 (1.078–3.308) in the dominant model.
PS method corroborated the result in the previous analyses finding an association between ATG2B rs3759601 
G allele and a higher risk to suffer from pharynx cancer (p = 0.035, OR = 2.721 (1.075–6.887)) (Table 6).
Finally, ATG16L1 rs2241880 CC genotypes still being associated with a higher risk to develop oral carcinoma 
after the PS application, p = 0.047 OR = 2.299(1.010–5.230) (Table 7).
Genotype
Control Larynx Pharynx Oral cavity
N % N % P-value OR (CI 95%) N % P-value OR (CI 95%) N % P-value OR (CI 95%)
ATG2B  
rs3759601
CC 106 41.9 98 46.0 / 1.00 63 38.2 / 1.00 28 38.9 / 1.00
CG 119 47.0 88 41.3 0.049 0.607 (0.369–0.999) 80 48.5 0.749 1.091 (0.640–1.858) 36 50.0 0.720 1.120 (0.603–2.080)
GG 28 11.1 27 12.7 0.921 1.041 (0.472–2.296) 22 13.3 0.016 2.613 (1.200–5.690) 8 11.1 0.522 1.391 (0.506–3.821)
Recessive
CC + CG 225 88.9 186 87.3 / 1.00 143 86.7 / 1.00 64 88.9 / 1.00
GG 28 11.1 27 12.7 0.444 1.339 (0.635–2.825) 22 13.3 0.013 2.493 (1.212–5.129) 8 11.1 0.583 1.301 (0.508–3.333)
Dominant
CC 106 41.9 98 46.0 / 1.00 63 38.2 / 1.00 28 38.9 / 1.00
CG + GG 147 58.1 115 54.0 0.103 0.675 (0.421–1.083) 102 61.8 0.282 1.317 (0.789–2.175) 44 61.1 0.630 1.158 (0.637–2.106)
ATG5  
rs2245214
CC 104 41.1 82 38.5 / 1.00 72 43.6 / 1.00 31 43.1 / 1.00
CG 124 49.0 105 49.3 0.369 1.256 (0.763–2.068) 79 47.9 0.624 0.879 (0.524–1.474) 31 43.1 0.348 0.744 (0.401–1.380)
GG 25 9.9 26 12.2 0.274 1.551 (0.707–3.401) 14 8.5 0.638 0.810 (0.337–1.946) 10 13.9 0.611 1.272 (0.503–3.216)
Recessive
CC + CG 228 90.1 187 87.8 / 1.00 151 91.5 / 1.00 62 86.1 / 1.00
GG 25 9.9 26 12.2 0.406 1.364 (0.656–2.837) 14 8.5 0.743 0.870 (0.380–1.993) 10 13.9 0.380 1.480 (0.617–3.552)
Dominant
CC 104 41.1 82 38.5 / 1.00 72 43.6 / 1.00 31 43.1 / 1.00
CG + GG 149 58.9 131 61.5 0.272 1.307 (0.811–2.107) 93 56.4 0.574 0.867 (0.527–1.426) 41 56.9 0.531 0.831 (0.465–1.485)
ATG10  
rs1864183
CC 93 36.8 70 32.9 / 1.00 46 27.9 / 1.00 27 37.5 / 1.00
CT 115 45.4 116 54.4 0.059 1.648 (0.981–2.770) 86 52.1 0.127 1.537 (0.885–2.670) 34 47.2 0.452 1.274 (0.678–2.392)
TT 45 17.8 27 12.7 0.946 1.026 (0.493–2.133) 33 20.0 0.201 1.594 (0.780–3.260) 11 15.3 0.875 0.931 (0.384–2.257)
Recessive
CC + CT 208 82.2 186 87.3 / 1.00 132 80.0 / 1.00 61 84.7 / 1.00
TT 45 17.8 27 12.7 0.415 0.760 (0.392–1.472) 33 20.0 0.517 1.232 (0.656–2.312) 11 15.3 0.612 0.812 (0.363–1.817)
Dominant
CC 93 36.8 70 32.9 / 1.00 46 27.9 / 1.00 27 37.5 / 1.00
CT + TT 160 63.2 143 67.1 0.118 1.484 (0.905–2.434) 119 72.1 0.100 1.552 (0.920–2.618) 45 62.5 0.587 1.180 (0.649–2.147)
ATG16L1  
rs2241880
TT 72 28.5 58 27.2 / 1.00 44 26.7 / 1.00 18 25.0 / 1.00
TC 130 51.3 108 50.7 0.597 1.157 (0.674–1.988) 81 49.1 0.551 1.194 (0.667–2.137) 31 43.1 0.860 1.066 (0.524–2.168)
CC 51 20.2 47 22.1 0.312 1.414 (0.722–2.769) 40 24.2 0.166 1.647 (0.813–3.335) 23 31.9 0.039 2.304 (1.043–5.093)
Recessive
TT + TC 202 79.8 166 77.9 / 1.00 125 75.8 / 1.00 49 68.1 / 1.00
CC 51 20.2 47 22.1 0.389 1.288 (0.724–2.292) 40 24.2 0.205 1.469 (0.810–2.666) 23 31.9 0.017 2.214 (1.150–4.263)
Dominant
TT 72 28.5 58 27.2 / 1.00 44 26.7 / 1.00 18 25.0 / 1.00
TC + CC 181 71.5 155 72.8 0.436 1.226 (0.735–2.046) 121 73.3 0.332 1.313 (0.758–2.276) 54 75.0 0.321 1.393 (0.724–2.682)
Table 3. Comparative results in selected ATG polymorphism distribution in laryngeal, pharyngeal and 
oral cavity cancer related to controls. P value & OR adjusted by sex, age, packs per year and SDU per week. 
Statistically significant results in bold.
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Discussion
HNSCC is consequence of genetic and environmental factors, mainly tobacco smoking and alcohol consumption. 
Autophagy is a complex pathway, modulated by different molecular mechanisms with an important interest in 
HNSCC development16. To show the possible association of polymorphisms in autophagy genes and the suscep-
tibility to suffer these tumours, a multicentre case-control study of head and neck squamous cell carcinoma was 
performed. Four polymorphisms were selected in ATG genes involved in phagosome generation. This was the 
case of the exonic missense polymorphisms ATG2B rs3759601, ATG16L1 rs2241880 and ATG10 rs1864183, and 
the intronic mutation in ATG5 rs2245214 which involves changes in the recognition sites for SRp40 transcription 
factor. ATG5, ATG10 and ATG16L1 code for proteins that form the Atg5-Atg12-Atg16L1 conjugation complex17, 
while Atg2B is necessary for closure of isolation membranes of autophagosomes18.
Analysis of laryngeal cancer showed an association between the less common allele genotypes (CT + TT) in 
ATG10 rs1864183 and a higher risk to develop it. It has been described that a lower expression of autophagy genes 
(ATG) accelerate tumour development due to a diminution in autophagy process19. ATG10 rs1864183 C > T var-
iant in exon 4 leads a catalytic change in the protein (Thr212Met) which causes a dysregulation in the autophago-
some formation and a higher risk to develop breast cancer20. In this situation the cell cannot degrade a damaged 
organ, collecting damaging substances that cause an increase in DNA damage and carcinogenesis. Although this 
polymorphism has never been studied in HNSCC, this result indicates the importance of the autophagy pathway 
in laryngeal tumour. We could hypothesize that less common allele genotypes (CT + TT) could be related with 
a lower autophagy and accumulation of DNA damage, related with a higher risk to develop laryngeal squamous 
cell carcinoma.
Though only associated in ATG2B rs3759601 heterozygosity (CG), there was a statistically significant 
result related with a lower risk of develop laryngeal cancer. However this result is difficult to explain due to its 
non-significance in dominant models. Nevertheless, there was a positive association between the homozygous 
GG genotype in the same polymorphism and an increase risk to suffer from pharyngeal squamous cell carcinoma. 
In mammals, there are two ATG2 genes which are functionally redundant21. Atg2B is an essential protein in the 
autophagy process due to it is essential for the autophagosome and lipid droplets formation19, 22. Mutations in 
ATG2B gene have been associated with colorectal and gastric cancer14. Atg2B rs3759601 C > G SNP in exon 25 
produces a protein change p.Gln1382Glu which could result in diminished autophagy and a higher risk to suffer 
pharyngeal cancer in our sample.
We did not find any significant result in the intronic ATG5 rs2245214 SNP distribution and HNSCC suscepti-
bility. This result can be related with the position of this polymorphism in the intronic region 6 of the ATG5 gene 
and the consequence of ineffective change in the protein function.
Finally, we found an association in the distribution of CC genotypes in the dominant and recessive mod-
els of ATG16L1 rs2241880 polymorphism and a higher risk to suffer from oral cavity squamous cell carcinoma. 
Autophagy-related 16-like 1 (ATG16L1) gene is a central adaptor in Atg5-Atg12-Atg16L1 complex formation and 
elongation of the autophagosome23. ATG16L1 variant rs2241880, a nonsynonymous 898 T > C polymorphism that 
encodes a threonine-to-alanine change (T300A), is associated with a decreased autophagy in Crohn's disease and 
higher inflammation23. In these studies CC genotype increases the secretion of TNF-α and IL-1β promoting a higher 
inflammation23. It has been also described that T300A variant enhances ATG16L1 cleavage by caspase 3, resulting in 
defective autophagy24 and chronic inflammatory state which increase Crohn´s disease susceptibility25 and colorectal 
cancer26. Likewise, it is known that ATG16L1-T300A SNP shows reduced affinity to bind the ATG16L1-binding motif 
and higher caspase-3 processing, causing a defective autophagy process27. Our results showed that CC genotypes were 
associated with an increased susceptibility to develop oral cavity squamous cell carcinoma maybe due to lower auto-
















P-valueN % N % N % N % N % N %
Age (years) 63.02 ± 8.566 56.30 ± 12.803 0.000 59.96 ± 8.41 59.52 ± 10.044 0.742 60.92 ± 10.008 62.24 ± 8.88 0.412
Sex
 Female 13 10.3 13 10.3
1.000
20 20.0 22 22.0
0.728
16 22.9 17 22.9
1.000
 Male 113 89.7 113 89.7 80 80.0 78 78.0 54 77.1 54 77.1
Tobacco smoking
 Never 7 5.5 7 5.5
0.944
7 7.0 8 8.0
0.943
7 10.0 7 10.0
1.000
 <20 PPY 20 15.9 22 17.5 22 22.0 23 23.0 12 17.1 12 17.1
 >20 PPY 99 78.6 97 77.0 71 71.0 69 69.0 51 72.9 51 72.9
 Missing 0 0 0 0 0 0 0 0 0 0 0 0
Alcohol drinking
 Never 53 42.1 51 40.5
0.904
26 26.0 27 27.0
0.985
23 32.9 23 32.9
1.000
 <14 SDU/week 28 22.2 31 24.6 30 30.0 30 30.0 19 27.1 19 27.1
 >14 SDU/week 45 35.7 44 34.9 44 44.0 43 43.0 28 40.0 28 40.0
 Missing 0 0 0 0 0 0 0 0 0 0 0 0
Table 4. Descriptive case-control study matched by the Propensity Score method. P-values related to controls. 
Statistically significant results in bold.
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In conclusion, this study provides evidence of the putative role of some polymorphisms in autophagy genes as 
a genetic susceptibility factor in head and neck squamous cell carcinogenesis. This is the first autophagy suscep-
tibility study in which cases and controls are matched by their risk factors, only taking into account their genetic 
background. Our finding emphasize the importance of autophagy in these tumours, the same as the heterogene-
ity between locations include under the same term of head and neck cancer. Additional studies in larger groups 
should be done and would be necessary to confirm our results.
Material and Methods
Study design. The data presented here is part of a multicentre study of three years of duration coordinated by 
the Medical Oncology Department of the University Hospital of Salamanca with the collaboration of 20 Spanish 
hospitals, all of them belonging to the Spanish Head & Neck Cancer Cooperative Group (TTCC).
The recruitment period extended from January 2012 to December 2014. The inclusion criteria were: adults 
diagnosed of HPV negative squamous cell carcinoma of larynx, pharynx or oral cavity. They were recruited in dif-
ferent Spanish hospitals that participate in the project after signing a written informed consent designed for this 
project according to local rules. The protocol of TTCC-2010–05 was initially approved by the TTCC Executive 
Committee, and then by the local institutional review board of University Hospital of Salamanca, according to 
country regulations. The research was conducted in full accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki and its later amendments and was consistent with Good Clinical Practice guidelines 
and the applicable local regulatory requirements.
455 patients diagnosed of HNSCC were included in the study. Controls were hospitalized patients without 
personal or familial history of cancer trying to be paired with cases by age, sex, smoking and alcoholism habit. 
They were recruited in different departments of the 20 hospitals. The initial sample size calculated for the control 
group was the same than the number of patients included in the study. However, this size was not reached due to 
the restricted inclusion criteria, so finally only 259 controls were included.
The information into socio-demographic and data informed by patient questionnaires were collected by 
auto-application, being supervised by the member of the research team with the objective of correct filled. 
Tumour clinic-pathological data were collected by oncologists following the TNM grading system reported by 
the American Joint Committee on Cancer (AJCC). All data were treated with the security measures establish in 
Genotype
Larynx Control
P-value* OR (CI 95%)N % N %
ATG2B rs3759601
CC 59 46.8 46 36.5 / 1.00
CG 52 41.3 69 54.8 0.028 0.535 (0.307–0.935)
GG 15 11.9 11 8.7 0.904 1.058 (0.423–2.644)
Recessive
CC + CG 111 88.1 115 91.3 / 1.00
GG 15 11.9 11 8.7 0.375 1.479 (0.624–3.506)
Dominant
CC 59 46.8 46 36.5 / 1.00
CG + GG 67 53.2 80 63.5 0.063 0.604 (0.355–1.028)
ATG5 rs2245214
CC 47 37.3 49 38.9 / 1.00
CG 63 50.0 66 52.4 0.725 1.105 (0.633–1.931)
GG 16 12.7 11 8.7 0.269 1.662 (0.675–4.089)
Recessive
CC + CG 110 87.3 115 91.3 / 1.00
GG 16 12.7 11 8.7 0.294 1.567 (0.677–3.627)
Dominant
CC 47 37.3 49 38.9 / 1.00
CG + GG 79 62.7 77 61.1 0.533 1.186 (0.693–2.031)
ATG10 rs1864183
CC 38 30.2 50 39.7 / 1.00
CT 70 55.5 58 46.0 0.020 2.004 (1.114–3.608)
TT 18 14.3 18 14.3 0.312 1.531 (0.671–3.494)
Recessive
CC + CT 108 85.7 108 85.7 / 1.00
TT 18 14.3 18 14.3 0.985 1.007 (0.481–2.110)
Dominant
CC 38 30.2 50 39.7 / 1.00
CT + TT 88 69.8 76 60.3 0.026 1.888 (1.078–3.308)
ATG16L1 rs2241880
TT 40 31.7 40 31.7 / 1.00
TC 62 49.3 66 52.4 0.930 1.027 (0.570–1.848)
CC 24 19.0 20 15.9 0.415 1.382 (0.635–3.010)
Recessive
TT + TC 102 81.0 106 84.1 / 1.00
CC 24 19.0 20 15.9 0.381 1.359 (0.684–2.701)
Dominant
TT 40 31.7 40 31.7 / 1.00
TC + CC 86 68.3 86 68.3 0.723 1.106 (0.633–1.935)
Table 5. Comparative results in selected ATG polymorphism distribution in risk factor-matched laryngeal 
cancer and controls. *P value & OR adjusted by age. Statistically significant results in bold.
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compliance with the Protection of Personal Data Organic Law 15/1999, 13th December, and safe-keeping by the 
University Hospital of Salamanca in its specific hospital server. Global study recruitment procedures and data 
collection have been previously described29.
DNA isolation and genotyping. DNA was extracted from leukocytes of peripheral blood tube by 
phenol-chloroform method. Four polymorphisms in important ATG genes (ATG2B rs3759601, ATG5 rs2245214, 
ATG10 rs1864183 and ATG16L1 rs2241880) were selected according to the following criteria: previously described 
association with illness susceptibility, >5% minor allele frequency in Caucasian population and published evidence 
of functionality. Genotyping of selected polymorphisms (Table 1) were analyzed by the allelic discrimination assay 
by TaqMan® probes (Applied biosystems), with specific oligonucleotides to amplify the polymorphic sequences and 
two labelled probes with the fluorochrome VIC and FAM to detect both alleles of each polymorphism. The reaction 
was performed using the specific PCR Master Mix in the Step-One Plus Real-Time PCR system (Applied biosys-
tems)30. To ensure the reproducibility, a 5% of random samples were re-genotyping. A total of 11 samples (5 patients 
and 6 controls) cannot be amplified due to low DNA quality rate and were excluded of the study.
Statistical analysis. Control group was tested for assumption of the Hardy-Weinberg equilibrium (HWE) 
by chi-squared test for each polymorphism (Table 1). The association between the different clinical and molecular 
variables was analyzed by cross tabs and the X2 test of Pearson. The Odds ratio (OR) and 95% confidence intervals 
were calculated by a logistic regression analysis. It was considered the existence of statistically significant differences 
where the P-value was < 0.05. These analyses were performed with the statistical software SPSS v.21.0 (IBM).
Because of the lower inclusion of matched controls, the statistical analysis was realized in two different ways. 
Firstly, patients were stratified according to its location (larynx, pharynx and oral cavity) comparing with the 
global control group (Table 2). To take into account the possible confounding variables, it was made a statistical 
adjustment for sex, and the continuous variables of age, packs of tobacco per year (PPY) and standard drink units 
of alcohol per week (SDU/week).
Secondly, we used the Propensity Score method (PS), a statistical term applied to the potent matching technique 
to equate groups in a cohort study31. Through a logistic regression analysis introducing the confounders as predictive 
variables, the method provides a numeric probability of each predictor group32. PS allows to pair the cases with the 
Genotype
Pharynx Control
P-value OR (CI 95%)N % N %
ATG2B rs3759601
CC 35 35.0 44 44.0 / 1.00
CG 48 48.0 49 49.0 0.494 1.231 (0.678–2.235)
GG 17 17.0 7 7.0 0.026 3.053 (1.139–8.182)
Recessive
CC + CG 83 83.0 93 93.0 / 1.00
GG 17 17.0 7 7.0 0.035 2.721 (1.075–6.887)
Dominant
CC 35 35.0 44 44.0 / 1.00
CG + GG 65 65.0 56 56.0 0.194 1.459 (0.825–2.580)
ATG5 rs2245214
CC 47 47.0 39 39.0 / 1.00
CG 45 45.0 52 52.0 0.265 0.718 (0.401–1.286)
GG 8 8.0 9 9.0 0.567 0.738 (0.260–2.092)
Recessive
CC + CG 92 92.0 91 91.0 / 1.00
GG 8 8.0 9 9.0 0.800 0.879 (0.325–2.379)
Dominant
CC 47 47.0 39 39.0 / 1.00
CG + GG 53 53.0 61 61.0 0.254 0.721 (0.411–1.265)
ATG10 rs1864183
CC 30 30.0 38 38.0 / 1.00
CT 51 51.0 47 47.0 0.316 1.374 (0.738–2.559)
TT 19 19.0 15 15.0 0.264 1.604 (0.700–3.676)
Recessive
CC + CT 81 81.0 85 85.0 / 1.00
TT 19 19.0 15 15.0 0.452 1.329 (0.633–2.792)
Dominant
CC 30 30.0 38 38.0 / 1.00
CT + TT 70 70.0 62 62.0 0.233 1.430 (0.794–2.575)
ATG16L1 rs2241880
TT 27 27.0 34 34.0 / 1.00
TC 48 48.0 49 49.0 0.522 1.234 (0.648–2.347)
CC 25 25.0 17 17.0 0.130 1.852 (0.835–4.108)
Recessive
TT + TC 75 75.0 83 83.0 / 1.00
CC 25 25.0 17 17.0 0.167 1.627 (0.816–3.247)
Dominant
TT 27 27.0 34 34.0 / 1.00
TC + CC 73 73.0 66 66.0 0.283 1.393 (0.761–2.551)
Table 6. Comparative results in selected ATG polymorphism distribution in risk factor-matched pharyngeal 
cancer and controls. Statistically significant results in bold.
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controls through the selection of a control sample with the same characteristics than patients regarding sex, tobacco 
and alcohol consumption. In this way both groups were are matched according to: packs of tobacco consumed per 
year (PPY): no smokers, <20PPY and >20PPY, standard drink units of alcohol per week (SDU/week): <14 SDU/
week and >14 SDU/week and sex (Table 4). As the Propensity Score method did not include the age of the indi-
viduals, in the second analysis age was introduced in the logistic regression as adjustment variable only in laryngeal 
carcinoma where this variable was statistically significant (p > 0.05 by ANOVA test).
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